Effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV (PWH) in routine clinical practice in Türkiye: 12-month outcomes from the KLIMIK HIV- TR cohort

Effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV (PWH) in routine clinical practice in Türkiye: 12-month outcomes from the KLIMIK HIV- TR cohort | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV (PWH) in routine clinical practice in Türkiye: 12-month outcomes from the KLIMIK HIV- TR cohort Halis AKALIN, Asuman İNAN, Bülent KAYA, Deniz GÖKENGİN, Dilara İNAN, and 11 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8852078/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 12 You are reading this latest preprint version Abstract Background Phase 3 trials have established the long‑term efficacy and safety of BIC/FTC/TAF for both treatment‑naïve and treatment‑experienced people with HIV (PWH). Real‑world evidence in patients with very high baseline viral load remains limited. Methods This was a non‑interventional, observational, retrospective analysis across 33 tertiary centers participating in the KLIMIK HIV‑TR cohort. Adults (≥18 years) who initiated single‑tablet BIC/FTC/TAF on or before August 31, 2022 were included. The primary endpoint was virologic suppression at week‑48, defined as HIV‑1 RNA <200 copies/mL. Suppression was further stratified by baseline viral load (100,000; >1,000,000 copies/mL). Results 2,262 patients were analyzed (1,122 treatment‑naïve [49.6%], 1,140 treatment‑experienced [50.4%]). Among treatment‑naïve patients, 88.5% had baseline HIV‑1 RNA >100,000 copies/mL and 24.2% >1,000,000 copies/mL; 55.7% had CD4 <350 cells/mm³. Virologic suppression (HIV-1 RNA <200 copies/mL) in treatment‑naïve patients was 95.6% and 98.3% at weeks 24 and 48 respectively. When a threshold of <50 copies/mL was used, virological suppression rates at weeks 24 and 48 were 81.9% and 93%, respectively. At week 24, virological suppression (HIV-1 RNA 100,000 versus <100,000 copies/mL (80.4% vs 93.8%; p1,000,000 versus <1,000,000 copies/mL (67.1% vs 86.9%; p<0.001). The median CD4/CD8 ratio increased from 0.44 at baseline to 1.06 at week 48 (p<0.001). No serious adverse events leading to discontinuation were observed. Conclusions High efficacy was observed even among treatment‑naïve patients with very high baseline viral loads, supporting its use in this population. Figures Figure 1 Figure 2 Figure 3 Figure 4 BACKGROUND Effective antiretroviral therapy (ART) plays a crucial role in controlling the HIV epidemic, reducing morbidity and mortality, and enabling life expectancy comparable to that of people without HIV. The introduction of integrase strand transfer inhibitors (INSTIs) has been a major advance in ART ( 1 ). Bictegravir is a second‑generation INSTI co‑formulated with emtricitabine and tenofovir alafenamide (BIC/FTC/TAF), recommended as a preferred initial regimen in international guidelines ( 2 , 3 ). Phase 3 studies have demonstrated durable efficacy and safety of BIC/FTC/TAF in both treatment-naive and treatment-experienced PWH ( 4 – 8 ). Switch studies have shown non‑inferior outcomes versus protease‑inhibitor‑based or dolutegravir‑based regimens ( 9 – 12 ). Real‑world cohorts generally report high suppression rates, but often include relatively few treatment‑naïve patients with very high baseline viral load ( 13 – 14 ). We aimed to evaluate 12‑month effectiveness and tolerability of BIC/FTC/TAF in routine practice across Türkiye, using data from the Turkish HIV-TR Cohort, with a specific focus on outcomes of patients with high baseline viral load. METHODS Study design and setting We conducted a retrospective, non‑interventional, observational cohort study across 33 tertiary centers participating in the KLIMIK HIV‑TR network, representing diverse geographic regions. Ethics approval was obtained from the Bursa Uludağ University Faculty of Medicine Clinical Research Ethics Committee (November 7, 2023; 2023‑23/22). This study was funded by Gilead Sciences. Participants Eligible adults (≥ 18 years) initiated single‑tablet BIC/FTC/TAF on or before August 31, 2022. Patients without ≥ 12 months of treatment and follow‑up by September 1, 2023 were excluded. Data captured included demographics, transmission category, opportunistic infections (CDC criteria), laboratory findings (including complete blood count, total cholesterol, HDL, LDL, triglycerides, non-HDL cholesterol [total cholesterol minus HDL], urea, creatinine), virologic and immunologic parameters, prior and current ART, and serious adverse events leading to ART discontinuation. Primary/early HIV infection was classified per EACS v13.0 ( 3 ). Outcomes The primary endpoint was virologic suppression at week 48 defined as HIV‑1 RNA < 200 copies/mL. In treatment‑naïve patients, suppression at weeks 4–8, 24, and 48 was also assessed using a threshold of < 50 copies/mL. Analyses were stratified by baseline viral load (100,000; >1,000,000 copies/mL). Secondary endpoints included change in CD4 count, increase in CD4/CD8 ratio, tolerability, and discontinuations due to drug-related adverse events. For treatment‑experienced patients, reasons for switching to BIC/FTC/TAF were recorded. Statistical analysis IBM Statistical Package for the Social Sciences (SPSS) for macOS, version 29.0 (IBM Corp., Armonk, NY) was used for analyses. Statistical significance was indicated as p < 0.05. Categorical variables are reported as frequency and percentage; continuous variables as median (25th–75th percentiles), minimum and maximum. Changes over time were evaluated using the Wilcoxon signed‑rank test. Patients with missing measurements within the prespecified windows (weeks 4–8, 24, 48) were treated as missing and excluded(M = E) from the respective analyses. RESULTS Baseline characteristics Of 2,667 individuals recorded in the electronic data system, 2,262 met inclusion criteria (1,122 treatment‑naïve; 1,140 treatment‑experienced). The demographics of the PWH included in the study are presented in Table 1. Table 1. The demographic and epidemiological characteristics of PWH Treatment-naive (TN) (n=1122, 49.6%) Treatment-experienced (TE) (n=1140, 50.4%) Overall Sex, n(%) Male 1001 (89.2) 1001 (87.8) 2002 (88.5) Female 121 (10.8) 139 (12.2) 260 (11.5) Age at diagnosis Mean ± SS 36±12 37±13 37±12 Median (Q25-Q75) 33 (26-44) 35 (27-46) 34 (27-45) Minimum-Maximum 18-73 18-78 18-78 History of primary/early HIV infection 215 143 368 Mode of transmission Homosexual / Bisexual 282 (25) 335 (29.4) 617 (27.3) Heterosexual 417 (37.2) 493 (43.2) 910 (40.2) Intravenous drug use 9 (0.8) 2 (0.2) 11 (0.5) Blood/blood products 13 (1.2) 7 (0.6) 20 (0.9) Pregnancy/lactation 0 (0) 1 (0.1) 1 (0) Nosocomial 2 (0.2) 7 (0.6) 9 (0.4) Unknown 368 (32.8) 279 (24.5) 647 (28.6) Other 31 (2.8) 16 (1.4) 47 (2.1) Comorbidities included hypertension (n=109), cardiovascular disease (n=34), type 2 diabetes mellitus (n=61), renal impairment (n=17), liver disease (n=17), and hyperlipidemia (n=116). Mean numbers of HIV‑1 RNA measurements during follow‑up were 3.0 in treatment‑naïve and 2.7 in treatment‑experienced patients. In treatment-naïve and treatment-experienced patients, HBsAg positivity was 3.2% and 5.2%; anti‑HCV positivity was 2.1% and 1.1%; RPR positivity was 24.0% and 16.1%, respectively. Latent tuberculosis was screened using PPD or Quantiferon tests; and identified in 8.1% (19/234 screened) of treatment‑naïve and 21.4% (62/290 screened) of treatment‑experienced patients. Among treatment‑naïve patients, 88.5% had baseline HIV‑1 RNA >100,000 copies/mL and 24.2% >1,000,000 copies/mL; 55.7% had CD4 <350 cells/mm³ at baseline. The virological and immunological status of patients prior to BIC/FTC/TAF initiation is presented in Table 2. Table 2. The virological and immunological status of treatment-naive and treatment-experienced patients prior to initiating BIC/FTC/TAF Parameters Treatment-Naive Treatment-Experienced n (%) or Median (Q25-Q75) n (%) or Median (Q25-Q75) Before B/F/TAF n=1122 n=1140 CD4 (count/mm 3 ) 315.5 (183-487.75) 577.5 (356.25-804.75) 350 497 (44.3) 863 (75.7) 200 815 (72.6) 1008 (88.4) CD4 / CD8 0.44 (0.30-0.71) 0.85 (0.47-1.22) HIV – RNA (c/mL) HIV – RNA (c/mL) log 10 447480.5 (163900-980000) 5.65 (5.21-5.99) 0.0 (0.0-32.0) N.D. >100.000 993 (88.5) 18 (1.6) >500.000 521 (46.4) 0 (0.0) >1.000.000 272 (24.2) 0 (0.0) >5.000.000 36 (0.03) 0 (0.0) >10.000.000 6 (0.005) 0 (0.0) N.D.: Not determined Treatment effectiveness Virological and immunological outcomes In treatment‑naïve patients, virological suppression rates (HIV-1 RNA <200 copies/mL) were 95.6% (at week 24) and 98.3% (at week 48). When a threshold of <50 copies/mL was used, virological suppression rates at weeks 24 and 48 were 81.9% and 93%, respectively. Virological suppression rates and suppression rates by baseline viral load in treatment-naive patients are presented in Figures 1, 2, and 3. Among treatment-naive patients with baseline HIV-1 RNA >100.000 copies/mL, the virological suppression rate (HIV-1 RNA <50 copies/mL) at week 24 was significantly lower compared to those with baseline HIV-1 RNA <100.000 copies/mL (80.4% vs. 93.8%, p<0.001). When using a threshold of <200 copies/mL, virological suppression rates at week 24 were 95% and 100%, respectively (p=0.028). No significant difference was observed in virological suppression rates at week 48 (98% vs. 100%, p=0.254). Among treatment-naive patients with baseline HIV-1 RNA >1.000.000 copies/mL, virological suppression rates (HIV-1 RNA <50 copies/mL) at weeks 24 and 48 were significantly lower compared to those with HIV-1 RNA <1.000.000 copies/mL (67.1% vs. 86.9%, p<0.001 and 88.4% vs. 94.5%, p=0.002, respectively). When using a threshold of HIV-1 RNA 1.000.000 copies/mL and 97% in those with <1.000.000 copies/mL (p5.000.000 copies/mL, virological suppression rates at week 48 (HIV-1 RNA <50 copies/mL and <200 copies/mL) did not differ significantly from those with baseline HIV-1 RNA <5.000.000 copies/mL (85.3% vs. 93.3%, p=0.083 and 94.1% vs. 98.4%, p=0.114, respectively) (Table 3). Table 3. Virological suppression rates in treatment-naive patients before initiating BIC/FTC/TAF, and at weeks 24 and 48 Among six treatment-naïve patients with baseline HIV-1 RNA >10.000.000 copies/mL; all five patients with available data at that time point achieved virological suppression (HIV-1 RNA <50 copies/mL) at week 48. In treatment‑experienced (switch) patients, week‑48 suppression was 92.2% (<50 copies/mL) and 96.5% (<200 copies/mL), compared to 85.6% and 92.5%, respectively, prior to switching. Among treatment-naive patients with a baseline CD4 count <350/mm ³ , virological suppression rates (HIV-1 RNA 350/mm ³ (77.3% vs. 87.9%, p<0.001 and 90.8% vs. 95.7%, p=0.002, respectively). Among treatment-naive patients with a CD4 count 100.000 copies/mL, virological suppression rates at week 24 were 76.1% and 93.3% using thresholds of <50 copies/mL and <200 copies/mL, respectively. At week 48, the corresponding suppression rates were 90.8% and 97.6%. When compared to patients with baseline HIV-1 RNA <100.000 copies/mL, virological suppression rates at week 24 (using a threshold of <50 copies/mL) were significantly lower (76.1% vs. 92.5%, p=0.029). Among treatment-naive patients with a CD4 count 1.000.000 copies/mL, virological suppression rates at week 24 were 65% and 89.6% using thresholds of <50 copies/mL and <200 copies/mL, respectively. At week 48, the corresponding suppression rates were 85.9% and 97.3%. Compared to patients with baseline HIV-1 RNA <1.000.000 copies/mL, virological suppression rates (threshold <50 copies/mL) at both week 24 and week 48 were significantly lower (65% vs. 83.5%, p350/mm ³ , only those with baseline HIV-1 RNA >1.000.000 copies/mL had lower virological suppression rates (threshold <50 copies/mL) at week 24 compared to those with baseline HIV-1 RNA <1.000.000 copies/mL (73.3% vs. 90.3%, p<0.001).Among patients with CD4 counts <200/mm ³ , the virological suppression rate (HIV-1 RNA <50 copies/mL) at week 48 was 91.6%. Among patients with CD4 counts 1.000.000 copies/mL, the virological suppression rate (VL <50 copies/mL) at week 48 was 87.8%. In treatment‑naïve patients, the median CD4/CD8 ratio increased from 0.44 at baseline to 1.06 at week 48 (p<0.001) (Figure 4). Change in CD4 count (ΔCD4 [cells/mm³]) had median (25th–75th) values of +139 (9.5–263.1) at weeks 4–8, +216 (85.75–358) at week 24, and +263 (91–416.5) at week 48; mean (±SD) changes were +136.3±211.7, +244.7±355.6, and +305.7±560.9, respectively. In treatment‑experienced patients, ΔCD4 median values were −26.5 (−256.5 to 159.25) at weeks 4–8, +86 (−100.0 to 257.0) at week 24, and +117.5 (−70.5 to 320.25) at week 48; mean changes were +67.6±376.1, +72.1±369.9, and +125.3±370.8, respectively. Virological and immunological outcomes in primary/early infection and older age Among 215 treatment‑naïve patients with primary/early infection, median CD4 was 310 (169–456) cells/mm³; 57% had CD4 <350 and 31.2% 100,000 and >1,000,000 copies/mL occurred in 93% and 28.4%, respectively. Virologic suppression at week 24 was 78.9% (<50 copies/mL) and 96.3% (<200 copies/mL); at week 48, corresponding suppression rates were 93.1% and 98.5%, respectively. Outcomes at week 48 were comparable to treatment‑naïve patients without primary/early infection. Among 68 treatment‑naïve patients aged ≥50 years, week‑48 virological suppression was 95% (<50 copies/mL) and 99% (<200 copies/mL). Safety and tolerability Baseline and week‑48 ALT, creatinine, and lipid parameters are summarized in Table 4. Non‑HDL cholesterol decreased significantly at week 48; total cholesterol/HDL ratios were comparable. Statin use during follow‑up was 8.5% (95/1122) among treatment‑naïve and 8.7% (99/1140) among treatment‑experienced patients. Table 4. Biochemical Parameters Before BIC/FTC/TAF Initiation and at Week 48 of Treatment Parameters N Before B/F/TAF week 48 p-value Median (Q25-Q75) Median (Q25-Q75) Treatment-Naive ALT 958 23 (18-29) 21 (14-29.1) <0.001 Creatinine 987 0.83 (0.70-0.98) 0.90 (0.78-1.00) <0.001 Non-HDL Cholesterol 918 125 (97-157) 120 (104-169) <0.001 Total Cholesterol/HDL Ratio 918 4.08 (3.25-4.93) 3.93 (3.23-4.93) 0.998 Treatment-Experienced ALT 1027 23 (18-28) 22 (16-30.4) 0.137 Creatinine 1043 0.90 (0.75-1.05) 0.90 (0.80-1.00) 0.001 Non-HDL Cholesterol 943 140 (106-171) 126 (104-176) <0.001 Total Cholesterol/HDL Ratio 943 4.05 (3.17-4.93) 3.93 (3.24-4.98) 0.839 Treatment discontinuation No serious adverse events leading to discontinuation were recorded. BIC/FTC/TAF discontinuation occurred in 1.7% (naïve) and 2.6% (experienced) of patients (Table 5). Table 5. Reasons for BIC/FTC/TAF Discontinuation Reasons for B/F/TAF Discontinuation (Naive) n (%) Patient's Decision 6 (31.6) Pregnancy 5 (26.3) Other 4 (21.1) Physician's Discretion 2 (10.5) Unknown 2 (10.5) Overall 19 (100) Reasons for B/F/TAF Discontinuation (Experienced) Unknown 13 (43.3) Prevent potential future toxicities 5 (16.7) Other 5 (16.7) Physician's Discretion 3 (10) Patient's Decision 2 (6.7) Pregnancy 2 (6.7) Overall 30 (100) Previous ART in Treatment-Experienced Patients Among treatment-experienced patients, prior regimens before switching to BIC/FTC/TAF were as follows: EVG/COBI/FTC/TAF in 729 patients (64%), EVG/COBI/FTC/TDF in 114 patients (10%), DTG-based regimens in 193 patients (16.9%), raltegravir-based regimens in 26 patients (2.2%), protease inhibitor-based regimens in 57 patients (4.9%), and other regimens in 23 patients (2%). The median duration of previous ART use before switch was 48 months (IQR: 29–72). Reasons for Switching to BIC/FTC/TAF in Treatment-Experienced Patients In treatment‑experienced patients, the most common reasons for switching to BIC/FTC/TAF were physician discretion, prevention of potential future toxicities, and treatment simplification (Table 6). Table 6. Reasons for Switching to BIC/FTC/TAF in Treatment-Experienced Patients Reasons for switching to BIC/FTC/TAF n (%) Physician's Discretion 406 (35.6) Prevent potential future toxicities 303 (26.6) Treatment simplification 128 (11.2) Other 91 (8) Unknown 70 (6.1) Patient's Decision 51 (4.5) Drug-drug interactions 29 (2.5) Adherence issues 19 (1.6) Intolerance / toxicity 16 (1.4) Virological failure 10 (0.9) Planned treatment interruption 5 (0.4) Nephrotoxicity 4 (0.4) Enhance the resistance barrier 4 (0.4) Immunological failure 4 (0.4) Overall 1140 (100) DISCUSSION Virological Suppression In our study, which included a considerable proportion of treatment-naive PWH with high baseline viral loads, BIC/FTC/TAF demonstrated high rates of virological suppression at both week 24 and week 48. Virological suppression rates were 95.6% and 98.3%, respectively, when using a threshold of < 200 copies/mL, and 81.9% and 93% when using a threshold of < 50 copies/mL. Real-world studies of BIC/FTC/TAF have reported virological suppression rates at week 48 (threshold < 50 copies/mL) ranging between 91.8% and 94% ( 13 – 17 ). In a meta-analysis of real-world studies, the virological suppression rate at week 48 (threshold < 50 copies/mL) was reported as 97% ( 18 ). In phase 3 studies of BIC/FTC/TAF, efficacy at week 48 in treatment-naive patients ranged from 89% to 92.4% (threshold < 50 copies/mL) ( 4 , 6 ). To date, both clinical trials and real-world studies have included a lower proportion of treatment-naive patients with high baseline viral loads compared to our study. An evaluation of the viral loads of patients included in the study indicates that baseline viral loads were higher compared to those reported in other studies ( 4 , 6 , 13 – 16 , 19 , 20 ). In real-world studies, the proportion of treatment-naive patients with baseline HIV-1 RNA > 100.000 c/mL ranges between 37.1% and 58.6%. ( 13 – 16 , 19 , 20 ). In clinical trials, this proportion was reported at 17%, whereas in our study it was 88.5%( 4 , 6 ). In real-world studies, the proportion of patients with HIV-1 RNA > 500.000 c/mL was reported as 18.7% and 22% in two separate studies, while a phase 3 study reported 4% of patients with HIV-1 RNA > 400.000 c/mL ( 6 , 15 , 20 ). In our study, the proportion of patients with baseline HIV-1 RNA > 500.000 c/mL was 46.4%, and 24.2% of patients had HIV-1 RNA > 1.000.000 c/mL at baseline. We consider that the higher rates observed may be due to the high rate of late presentation in our cohort (with 51.5% of patients in the primary/early infection–negative group having a CD4 count 100.000 c/mL and > 1.000.000 c/mL were found to significantly affect virological suppression rates at week 24. A similar pattern was observed in patients with higher baseline viral loads. Our findings support that in patients with high baseline viral loads, virological suppression may not be achieved by week 24, but may be achieved at substantially higher rates by week 48. Notably, despite the markedly higher proportion of treatment-naive patients with high baseline viral loads compared to other studies, the achievement of virological suppression rates comparable to those reported in the literature highlights the high efficacy of BIC/FTC/TAF. In patients with high baseline viral loads, lack of virological suppression at week 24 should not be a cause for concern; instead, the trajectory of viral load decline should be assessed, and follow-up should be conducted at appropriate intervals. Regarding the potential impact of baseline CD4 counts on this outcome, the proportion of patients with baseline CD4 < 350/mm ³ ranged from 33% to 35% in phase 3 studies and from 47.4% to 57% in real-world studies. The proportion of patients with CD4 counts < 200/mm ³ ranged from 11% to 14% in phase 3 studies and from 27.4% to 42% in real-world studies ( 4 , 6 , 13 – 16 ). In our study, these proportions were 55.7% and 27.4%, respectively. In a subgroup analysis of two Phase 3 studies, Rampogal et al. reported a virological suppression rate (< 50 c/mL) of 99% at week 48 among 73 treatment-naive patients with baseline CD4 counts < 200/mm ³ . Among 39 patients with CD4 counts < 200/mm ³ and HIV-1 RNA ≥ 100.000 c/mL, the virological suppression rate was reported as 97% ( 21 ). Camacho et al. reported a virological suppression rate of 86.1% at week 48 in late presenters ( 22 ). The virological suppression rate at week 48 was 91.6% in treatment-naive patients with baseline CD4 counts < 200/mm ³ in our study. In our study, the association between a baseline CD4 count 350/mm ³ remained significant across all baseline viral load levels. Immune Recovery In our study, the median increase in CD4 count at week 48 in treatment-naïve patients was + 263 (IQR 91–416.5). The mean increase was + 305.7 ± 560.9. In phase 3 studies, this increase ranged from + 180 to + 233, while in the real-world BICSTaR study, the median increase was + 214 (IQR 120–380). In the BICSTaR study, the proportion of patients with CD4 < 200/mm ³ was 27.4%, and the proportion with CD4 100.000 c/mL was reported as 37.1% ( 13 ). In Phase 3 studies, the proportion of patients with CD4 counts < 200/mm ³ ranged from 11% to 14%, and those with CD4 counts 100.000 c/mL was reported to range from 17% to 21% ( 4 , 6 , 13 ). In our study, 55.7% of treatment-naive patients had CD4 counts < 350/mm ³ , 27.4% had CD4 counts 100.000 c/mL. We consider that the high proportion of patients with low CD4 counts and the high rate of primary/early infection in our study may explain the significant increases observed in CD4 counts. Primary / Early Infection In a study by Ambrosioni et al., including 64 patients with primary/early infection the rate of virological supression was reported as 93% ( 23 ). In our study, including 215 individuals with primary/early infection, the virological suppression rate (< 50 c/mL) at week 48 was comparable at 93.1%. Treatment-Experienced Patients In treatment-experienced (switch) patients, the virological suppression rate at week 48 (< 50 c/mL) was 92.2%. In real-world studies, this rate is observed to range between 93.3% and 97% ( 11 , 12 , 13 , 18 ), while in phase 3 studies, it has been reported between 92% and 94% ( 9 , 10 ). In our study, the mean change in CD4 count at week 48 was + 125.3/mm³. In previous studies, this change has been reported to range from a mean of − 31 to + 32 cells/mm³ ( 9 , 10 , 11 , 13 ). We consider that the duration of antiretroviral therapy prior to the switch may have contributed to these differences. Treatment Discontinuation and Safety In our study, the overall treatment discontinuation rate was 1.7% in treatment-naïve patients and 2.6% in treatment-experienced patients. Esser et al. reported treatment discontinuation rates of 5% in treatment-naïve patients and 10% in treatment-experienced patients. Nasreddine et al. reported these rates as 8.3% and 6.1%, respectively ( 13 , 17 ). In our study, no treatment discontinuations due to drug-related adverse effects were observed. In phase studies, the discontinuation rate due to adverse effects in treatment-naïve patients ranged between 0% and 2%, while in real-world studies, it was reported as 3.7% ( 4 , 6 , 17 ). In the switch studies, rates between 0% and 2% were reported ( 9 , 10 , 11 , 12 ). We were unable to perform pre-treatment antiretroviral resistance testing in our study. We believe this was due to the limited number of centers in our country that perform resistance testing and delays in obtaining test results. On the other hand, no resistance mutations associated with bictegravir have been demonstrated in studies. Sax et al. reported no treatment-emergent resistance during a 5-year follow-up period ( 8 , 24 ). Similarly, a very recent study conducted in our country found no resistance mutations associated with integrase inhibitors in treatment-naïve patients ( 25 ). Our study has some limitations. These include its retrospective design, lack of monitoring for mild to moderate adverse events, absence of resistance data, unmonitored weight changes in patients, and a shorter follow-up period compared to the 240-week follow-up in studies 1489 and 1490. However, the strengths of our study are notable. First, it represents the largest multicenter real-world study conducted in Türkiye to date on BIC/FTC/TAF, actively involving 33 centers from various geographic regions. Secondly, it is the study that has included patients with the highest baseline viral loads among all studies conducted worldwide to date. Thirdly, it provides a detailed analysis of both virological and immunological responses in treatment-naive patients with low and high baseline viral loads. CONCLUSIONS BIC/FTC/TAF demonstrated both safety and efficacy in treatment-naive and treatment-experienced patients. Efficacy rates were particularly high in treatment-naive patients with high baseline viral loads, indicating that it can be used safely in this population. Abbreviations BIC/FTC/TAF: bictegravir/emtricitabine/tenofovir alafenamide PWH: people with HIV KLİMİK: Turkish Society of Clinical Microbiology and Infectious Diseases ART: Antiretroviral Therapy INSTI: Integrase Strand Transfer Inhibitors Declarations This study was funded by Gilead Sciences. There is no conflict of interests. Clinical trial number: not applicable. Human Ethics and Consent to Participate declarations: not applicable. Availability of data and materials: Corresponding author Halis Akalın [email protected] Acknowledgments We would like to thank Dr. Guniz Kayahan and Dr. Ahmet Yilmaz from Gilead Sciences Türkiye for their support. We would like to thank Cem Şener from İNSİDANS for the biostatistical evaluation. AI was used for graphical abstract. Author Contribution HA and VK proposed and developed research question. HA wrote the first draft of the manuscript. VK conducted the critical review. All authors contributed the study design, interpretation of data and the revision of the manuscript. All authors have seen and contributed to the final version of manuscript. References Peters E, Iwuji C. Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: a scoping review. Antivir Ther. 2023;:1–15. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Updated Sep 25, 2025. Accessed Dec 15, 2025. European AIDS Clinical Society (EACS). Guidelines v13.0. Accessed Dec 15, 2025. Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, et al. Bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir/abacavir/lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390:2063–72. Wahl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir/abacavir/lamivudine for initial treatment of HIV-1: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6:e355–63. Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390:2073–82. Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, et al. Fixed-dose bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020;7:e389–400. Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E, et al. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. EClinicalMedicine. 2023;59:101991. Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48-week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e347–56. Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, López-Cortés L, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir plus abacavir/lamivudine in virologically suppressed adults with HIV-1: 48-week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e357–65. Gan L, Xie X, Fu Y, Yang X, Ma S, Kong L, et al. Bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir plus lamivudine for switch therapy in patients with HIV-1 infection: a real-world cohort study. Infect Dis Ther. 2023;12:2581–93. Sax PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, Ward D, Trottier B, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults with HIV. Clin Infect Dis. 2021;73(2):e485–93. Esser S, Brunetta J, Inciarte A, Levy I, D’Arminio Monforte A, Lambert JS, et al. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: real-world insights from BICSTaR cohorts. HIV Med. 2024;25:440–53. D’Arminio Monforte A, Tavelli A, Di Biaggio A, Sarmati L, Marchetti GC, Bai F, et al. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort. J Antimicrob Chemother. 2024;79:1279–88. Torralba M, Rodríguez G, Gasca FJG, Cuadra F, Barberá J, Geijo P, et al. Bictegravir/emtricitabine/tenofovir alafenamide in a multicentre cohort: real-life experience from Spain. Ann Pharmacother. 2024;58(2):140–7. Ambrosioni J, Lievano JR, Berrocal L, Inciarte A, de la Mora L, González-Cordón A, et al. Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre. J Antimicrob Chemother. 2022;77:1133–9. Nasreddine R, Florence E, Yombi JC, Henrard S, Darcis G, Van Praet J, et al. Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium. HIV Med. 2023;24:914–24. Chivite I, Berrocal L, de Lazzari E, Navadeh S, Lluis-Ganella C, Inciarte A, et al. Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV using real-world data: a systematic review and meta-analysis. J Antimicrob Chemother. 2024;79:1775–83. Crupi L, Parodi A, Cenderello G, Muccio M, Blanchi S, Randazzo N, et al. Impact of baseline plasma HIV-1 RNA and viral subtype on achievement of virological suppression in people with HIV treated with bictegravir/emtricitabine/tenofovir alafenamide in clinical practice. Sex Transm Infect. 2025;101(Suppl 1):A1–207. Begovac J, Lisicar I, Pintar VR, Zidovec-Lepej S, Planinic A, Zekan S. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide introduced at the first clinical visit: a real-life single-centre retrospective cohort study. Infect Dis Ther. 2025;14:867–80. Rampogal M, Wurapa A, Baumgarten A, Berhe M, Pozniak A, Orkin C et al. Five-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two phase 3 randomized clinical trials. Presented at: IDWeek 2022; Oct 19–23, 2022; Washington, DC, USA. Corona D, Pérez-Valero I, Camacho A, Liarte AG, Montero-Alonso M, Alemán MR, et al. Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters. Int J Antimicrob Agents. 2024;63:107016. Ambrosioni J, de Lazzari E, Suanzes P, Busca C, Ruperta LR, Orviz E et al. Bictegravir/emtricitabine/tenofovir alafenamide for the treatment of primary HIV infection: the DIC-PHI clinical trial. Presented at: AIDS 2024; Jul 22–26, 2024; Munich, Germany. Blanco-Arevalo JL, García-Deltoro M, Torralba M, Vélez-Díaz-Pallares M, Castro A, Rubio-Rodríguez D, et al. HIV-1 resistance and virologic failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature review. AIDS Rev. 2024;26:67–79. Özdemir A, Demir T, Polat C, Mertcan U, Sönmezer MÇ, Ergünay K, Ünal S, İnkaya AÇ, Pınar A. Molecular epidemiology and antiretroviral drug resistance profile, including capsid inhibitors, among treatment-naïve individuals with HIV-1 in Türkiye. HIV Med. 2025;:1–9. Epub ahead of print. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Under Review Version 1 posted Editorial decision: Revision requested 10 Apr, 2026 Reviews received at journal 05 Apr, 2026 Reviews received at journal 04 Apr, 2026 Reviewers agreed at journal 30 Mar, 2026 Reviewers agreed at journal 25 Mar, 2026 Reviews received at journal 09 Mar, 2026 Reviewers agreed at journal 09 Mar, 2026 Reviewers agreed at journal 06 Mar, 2026 Reviewers invited by journal 06 Mar, 2026 Editor assigned by journal 14 Feb, 2026 Submission checks completed at journal 13 Feb, 2026 First submitted to journal 11 Feb, 2026 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8852078","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":603448083,"identity":"f7d3faa2-3994-4cde-b0f1-fe501990c16b","order_by":0,"name":"Halis AKALIN","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA2ElEQVRIiWNgGAWjYBACAwbmhgMMFQwyDAwJID4zMVoYgVrOMPAgtLARoYWBsY0ULebsBxsP/px3mMfgePLjFwwV1okN8r0P8Gqx7ElsOMy7DajlzDMzC4Yz6YkNbOwG+B12AKiFEaTlRoKZAWPbYaAWAi4zOP+w4eDPOSAt6d8MGP8Ro+VGYsMB3gaQlhzjB4wNRGl5CFR/LJ1H8sybMoaEY+nGbWxphByWfPjjjxprOb7j6Zs/fKixlu1nPoZfCzJgk0hgIBwtKID5AymqR8EoGAWjYOQAAJQMS7a+WiE5AAAAAElFTkSuQmCC","orcid":"","institution":"Bursa Uludağ University","correspondingAuthor":true,"prefix":"","firstName":"Halis","middleName":"","lastName":"AKALIN","suffix":""},{"id":603448084,"identity":"3cb003c1-2433-4534-81fd-96b965df2ab8","order_by":1,"name":"Asuman İNAN","email":"","orcid":"","institution":"Haydarpaşa Numune Eğitim ve Araştırma Hastanesi","correspondingAuthor":false,"prefix":"","firstName":"Asuman","middleName":"","lastName":"İNAN","suffix":""},{"id":603448085,"identity":"682a16ae-4e2f-40fd-b46b-230d42b6e96f","order_by":2,"name":"Bülent KAYA","email":"","orcid":"","institution":"Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi","correspondingAuthor":false,"prefix":"","firstName":"Bülent","middleName":"","lastName":"KAYA","suffix":""},{"id":603448086,"identity":"3a906191-faad-4a67-80c0-e3e8f2d43622","order_by":3,"name":"Deniz GÖKENGİN","email":"","orcid":"","institution":"Ege University","correspondingAuthor":false,"prefix":"","firstName":"Deniz","middleName":"","lastName":"GÖKENGİN","suffix":""},{"id":603448087,"identity":"82ff90b6-0012-41c8-8784-b85a96b8ca6c","order_by":4,"name":"Dilara İNAN","email":"","orcid":"","institution":"Akdeniz University","correspondingAuthor":false,"prefix":"","firstName":"Dilara","middleName":"","lastName":"İNAN","suffix":""},{"id":603448088,"identity":"5cc3d25e-411d-4e29-8e8a-0d86942de857","order_by":5,"name":"Levent GÖRENEK","email":"","orcid":"","institution":"Sultan 2. Abdülhamid Han Eğitim ve Araştırma Hastanesi","correspondingAuthor":false,"prefix":"","firstName":"Levent","middleName":"","lastName":"GÖRENEK","suffix":""},{"id":603448089,"identity":"25a27d73-6064-44e7-8873-750ed42dcc6c","order_by":6,"name":"Hülya ÖZKAN ÖZDEMİR","email":"","orcid":"","institution":"Izmir Bozyaka Eğitim ve Araştırma Hastanesi","correspondingAuthor":false,"prefix":"","firstName":"Hülya","middleName":"ÖZKAN","lastName":"ÖZDEMİR","suffix":""},{"id":603448090,"identity":"a6d9f05f-84d3-45d9-b674-3220317aede5","order_by":7,"name":"Adalet ALTUNSOY","email":"","orcid":"","institution":"Ankara Bilkent City Hospital","correspondingAuthor":false,"prefix":"","firstName":"Adalet","middleName":"","lastName":"ALTUNSOY","suffix":""},{"id":603448091,"identity":"0570d825-2cbd-489d-8dbd-024e63806c18","order_by":8,"name":"Mehtap AYDIN","email":"","orcid":"","institution":"Ümraniye Eğitim ve Araştırma Hastanesi","correspondingAuthor":false,"prefix":"","firstName":"Mehtap","middleName":"","lastName":"AYDIN","suffix":""},{"id":603448092,"identity":"e1963888-8419-4a1f-9c75-92312dbeb485","order_by":9,"name":"Funda ŞİMŞEK","email":"","orcid":"","institution":"Okmeydanı Eğitim ve Araştırma Hastanesi","correspondingAuthor":false,"prefix":"","firstName":"Funda","middleName":"","lastName":"ŞİMŞEK","suffix":""},{"id":603448093,"identity":"063e9b09-08d0-4b2d-89b0-dbb16cc2a9ad","order_by":10,"name":"Atahan ÇAĞATAY","email":"","orcid":"","institution":"Istanbul University","correspondingAuthor":false,"prefix":"","firstName":"Atahan","middleName":"","lastName":"ÇAĞATAY","suffix":""},{"id":603448094,"identity":"6da4d00a-cb79-476f-be87-0145dc9539a3","order_by":11,"name":"Selda SAYIN KUTLU","email":"","orcid":"","institution":"Pamukkale University","correspondingAuthor":false,"prefix":"","firstName":"Selda","middleName":"SAYIN","lastName":"KUTLU","suffix":""},{"id":603448095,"identity":"b56f9cec-409c-4fb9-b007-121d9e4f0a73","order_by":12,"name":"Ali ASAN","email":"","orcid":"","institution":"Bursa Yuksek Ihtisas Egitim Ve Arastirma Hastanesi","correspondingAuthor":false,"prefix":"","firstName":"Ali","middleName":"","lastName":"ASAN","suffix":""},{"id":603448096,"identity":"d126fcf9-1e3e-438a-86e1-b83ad225c79f","order_by":13,"name":"Sabri ATALAY","email":"","orcid":"","institution":"Izmir Tepecik Eğitim ve Araştırma Hastanesi","correspondingAuthor":false,"prefix":"","firstName":"Sabri","middleName":"","lastName":"ATALAY","suffix":""},{"id":603448097,"identity":"d9903cbc-bc91-4f1a-b6ff-13137be232b8","order_by":14,"name":"Serhat BİRENGEL","email":"","orcid":"","institution":"Ankara University","correspondingAuthor":false,"prefix":"","firstName":"Serhat","middleName":"","lastName":"BİRENGEL","suffix":""},{"id":603448098,"identity":"1d7b6b07-628f-45ab-a973-f80adebd534f","order_by":15,"name":"Volkan KORTEN","email":"","orcid":"","institution":"Marmara Üniversitesi Eğitim ve Araştırma Hastanesi","correspondingAuthor":false,"prefix":"","firstName":"Volkan","middleName":"","lastName":"KORTEN","suffix":""}],"badges":[],"createdAt":"2026-02-11 13:08:48","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8852078/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8852078/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":104781488,"identity":"ffdf20f1-b7ac-4bba-8545-c17cdc483b81","added_by":"auto","created_at":"2026-03-17 07:55:47","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":80334,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eVirological suppression at weeks 4–8, 24, and 48 in treatment-naive patients\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-8852078/v1/b895c0cd5f144d0b2e2f9784.png"},{"id":104547289,"identity":"94fc64f4-2c17-4022-a634-94a83b5722f9","added_by":"auto","created_at":"2026-03-13 07:34:56","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":122747,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eVirological suppression in PWH with baseline viral loads below and above 100.000 copies/mL\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-8852078/v1/6e845df96c06feccd7bab345.png"},{"id":104547292,"identity":"2ed53b9f-9f96-4b95-8312-a45d456c8a21","added_by":"auto","created_at":"2026-03-13 07:34:56","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":113000,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eVirological suppression rates in PWH with baseline viral loads below and above 1.000.000 copies/mL\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-8852078/v1/3f5d384ad57286fc73104a8d.png"},{"id":104547290,"identity":"f8c8462e-25aa-40cf-999f-71e0da9b46c2","added_by":"auto","created_at":"2026-03-13 07:34:56","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":108820,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eChanges in CD4 count and CD4/CD8 ratio in treatment-naive patients.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-8852078/v1/d5a5439d4920699e107da421.png"},{"id":104786067,"identity":"37b03ee5-9a89-4e1d-ab2b-37a0b7a5aaa9","added_by":"auto","created_at":"2026-03-17 08:14:31","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1983077,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8852078/v1/02d53633-71e1-4d59-bf38-05e0da3690d2.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV (PWH) in routine clinical practice in Türkiye: 12-month outcomes from the KLIMIK HIV- TR cohort","fulltext":[{"header":"BACKGROUND","content":"\u003cp\u003eEffective antiretroviral therapy (ART) plays a crucial role in controlling the HIV epidemic, reducing morbidity and mortality, and enabling life expectancy comparable to that of people without HIV. The introduction of integrase strand transfer inhibitors (INSTIs) has been a major advance in ART (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eBictegravir is a second‑generation INSTI co‑formulated with emtricitabine and tenofovir alafenamide (BIC/FTC/TAF), recommended as a preferred initial regimen in international guidelines (\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e \u003cp\u003ePhase 3 studies have demonstrated durable efficacy and safety of BIC/FTC/TAF in both treatment-naive and treatment-experienced PWH (\u003cspan additionalcitationids=\"CR5 CR6 CR7\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eSwitch studies have shown non‑inferior outcomes versus protease‑inhibitor‑based or dolutegravir‑based regimens (\u003cspan additionalcitationids=\"CR10 CR11\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eReal‑world cohorts generally report high suppression rates, but often include relatively few treatment‑na\u0026iuml;ve patients with very high baseline viral load (\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e). We aimed to evaluate 12‑month effectiveness and tolerability of BIC/FTC/TAF in routine practice across T\u0026uuml;rkiye, using data from the Turkish HIV-TR Cohort, with a specific focus on outcomes of patients with high baseline viral load.\u003c/p\u003e"},{"header":"METHODS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy design and setting\u003c/h2\u003e \u003cp\u003e We conducted a retrospective, non‑interventional, observational cohort study across 33 tertiary centers participating in the KLIMIK HIV‑TR network, representing diverse geographic regions. Ethics approval was obtained from the Bursa Uludağ University Faculty of Medicine Clinical Research Ethics Committee (November 7, 2023; 2023‑23/22). This study was funded by Gilead Sciences.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eParticipants\u003c/h3\u003e\n\u003cp\u003eEligible adults (\u0026ge;\u0026thinsp;18 years) initiated single‑tablet BIC/FTC/TAF on or before August 31, 2022. Patients without \u0026ge;\u0026thinsp;12 months of treatment and follow‑up by September 1, 2023 were excluded. Data captured included demographics, transmission category, opportunistic infections (CDC criteria), laboratory findings (including complete blood count, total cholesterol, HDL, LDL, triglycerides, non-HDL cholesterol [total cholesterol minus HDL], urea, creatinine), virologic and immunologic parameters, prior and current ART, and serious adverse events leading to ART discontinuation. Primary/early HIV infection was classified per EACS v13.0 (\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e\n\u003ch3\u003eOutcomes\u003c/h3\u003e\n\u003cp\u003eThe primary endpoint was virologic suppression at week 48 defined as HIV‑1 RNA\u0026thinsp;\u0026lt;\u0026thinsp;200 copies/mL. In treatment‑na\u0026iuml;ve patients, suppression at weeks 4\u0026ndash;8, 24, and 48 was also assessed using a threshold of \u0026lt;\u0026thinsp;50 copies/mL. Analyses were stratified by baseline viral load (\u0026lt;\u0026thinsp;100,000; \u0026gt;100,000; \u0026gt;1,000,000 copies/mL).\u003c/p\u003e \u003cp\u003eSecondary endpoints included change in CD4 count, increase in CD4/CD8 ratio, tolerability, and discontinuations due to drug-related adverse events. For treatment‑experienced patients, reasons for switching to BIC/FTC/TAF were recorded.\u003c/p\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eIBM Statistical Package for the Social Sciences (SPSS) for macOS, version 29.0 (IBM Corp., Armonk, NY) was used for analyses. Statistical significance was indicated as p\u0026thinsp;\u0026lt;\u0026thinsp;0.05. Categorical variables are reported as frequency and percentage; continuous variables as median (25th\u0026ndash;75th percentiles), minimum and maximum. Changes over time were evaluated using the Wilcoxon signed‑rank test. Patients with missing measurements within the prespecified windows (weeks 4\u0026ndash;8, 24, 48) were treated as missing and excluded(M\u0026thinsp;=\u0026thinsp;E) from the respective analyses.\u003c/p\u003e \u003c/div\u003e"},{"header":"RESULTS","content":"\u003cp\u003e\u003cstrong\u003eBaseline characteristics\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eOf 2,667 individuals recorded in the electronic data system, 2,262 met inclusion criteria (1,122 treatment‑na\u0026iuml;ve; 1,140 treatment‑experienced). The demographics of the PWH included in the study are presented in Table 1.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 1. The demographic and epidemiological characteristics of PWH\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"713\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTreatment-naive\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(TN)\u003cbr\u003e\u0026nbsp;(n=1122, 49.6%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTreatment-experienced (TE)\u0026nbsp;\u003cbr\u003e\u0026nbsp;(n=1140, 50.4%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eOverall\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSex, n(%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003eMale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e1001 (89.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e1001 (87.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e2002 (88.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003eFemale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e121 (10.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e139 (12.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e260 (11.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge at diagnosis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003eMean \u0026plusmn; SS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e36\u0026plusmn;12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e37\u0026plusmn;13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e37\u0026plusmn;12\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003eMedian (Q25-Q75)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e33 (26-44)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e35 (27-46)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e34 (27-45)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003eMinimum-Maximum\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e18-73\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e18-78\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e18-78\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHistory of primary/early HIV infection\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e215\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e143\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e368\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMode of transmission\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003eHomosexual / Bisexual\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e282 (25)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e335 (29.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e617 (27.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003eHeterosexual\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e417 (37.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e493 (43.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e910 (40.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003eIntravenous drug use\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e9 (0.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e2 (0.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e11 (0.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003eBlood/blood products\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e13 (1.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e7 (0.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e20 (0.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003ePregnancy/lactation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e0 (0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e1 (0.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e1 (0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003eNosocomial\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e2 (0.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e7 (0.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e9 (0.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003eUnknown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e368 (32.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e279 (24.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e647 (28.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 250px;\"\u003e\n \u003cp\u003eOther\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 198px;\"\u003e\n \u003cp\u003e31 (2.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e16 (1.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e47 (2.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eComorbidities included hypertension (n=109), cardiovascular disease (n=34), type 2 diabetes mellitus (n=61), renal impairment (n=17), liver disease (n=17), and hyperlipidemia (n=116).\u003c/p\u003e\n\u003cp\u003eMean numbers of HIV‑1 RNA measurements during follow‑up were 3.0 in treatment‑na\u0026iuml;ve and 2.7 in treatment‑experienced patients. In treatment-na\u0026iuml;ve and treatment-experienced patients, HBsAg positivity was 3.2% and 5.2%; anti‑HCV positivity was 2.1% and 1.1%; RPR positivity was 24.0% and 16.1%,\u003cu\u003e\u0026nbsp;\u003c/u\u003erespectively. Latent tuberculosis was screened using PPD or Quantiferon tests; and identified in 8.1% (19/234 screened) of treatment‑na\u0026iuml;ve and 21.4% (62/290 screened) of treatment‑experienced patients.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAmong treatment‑na\u0026iuml;ve patients, 88.5% had baseline HIV‑1 RNA \u0026gt;100,000 copies/mL and 24.2% \u0026gt;1,000,000 copies/mL; 55.7% had CD4 \u0026lt;350 cells/mm\u0026sup3; at baseline. The virological and immunological status of patients prior to BIC/FTC/TAF initiation is presented in Table 2.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2. The virological and immunological status of treatment-naive and treatment-experienced patients prior to initiating BIC/FTC/TAF\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"604\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 170px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eParameters\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTreatment-Naive\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTreatment-Experienced\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e\u003cstrong\u003en (%) or Median (Q25-Q75)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e\u003cstrong\u003en (%) or Median (Q25-Q75)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eBefore B/F/TAF\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003en=1122\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003en=1140\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCD4 (count/mm\u003csup\u003e3\u003c/sup\u003e)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e315.5 (183-487.75)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e577.5 (356.25-804.75)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u0026lt;350\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e625 (55.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e277 (24.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u0026gt;350\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e497 (44.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e863 (75.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u0026lt;200\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e307 (27.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e132 (11.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u0026gt;200\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e815 (72.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e1008 (88.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCD4 / CD8\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e0.44 (0.30-0.71)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e0.85 (0.47-1.22)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHIV \u0026ndash; RNA (c/mL)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eHIV \u0026ndash; RNA (c/mL)\u0026nbsp;\u003c/strong\u003elog\u003csub\u003e10\u003c/sub\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e447480.5 (163900-980000)\u003c/p\u003e\n \u003cp\u003e5.65 (5.21-5.99)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e0.0 (0.0-32.0)\u003c/p\u003e\n \u003cp\u003eN.D.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u0026gt;100.000\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e993 (88.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e18 (1.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u0026gt;500.000\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e521 (46.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e0 (0.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u0026gt;1.000.000\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e272 (24.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e0 (0.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u0026gt;5.000.000\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e36 (0.03)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e0 (0.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 170px;\"\u003e\n \u003cp\u003e\u0026gt;10.000.000\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e6 (0.005)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 217px;\"\u003e\n \u003cp\u003e0 (0.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eN.D.: Not determined\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTreatment effectiveness\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eVirological and immunological outcomes\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn\u0026nbsp;treatment‑na\u0026iuml;ve patients, virological suppression rates (HIV-1 RNA \u0026lt;200 copies/mL) were 95.6% (at week 24) and 98.3% (at week 48).\u0026nbsp;When a threshold of \u0026lt;50 copies/mL was used, virological suppression rates at weeks 24 and 48 were 81.9% and 93%, respectively.\u003cu\u003e\u0026nbsp;\u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eVirological suppression rates and suppression rates by baseline viral load in treatment-naive patients are presented in Figures 1, 2, and 3.\u003c/p\u003e\n\u003cp\u003eAmong treatment-naive patients with baseline HIV-1 RNA \u0026gt;100.000 copies/mL, the virological suppression rate (HIV-1 RNA \u0026lt;50 copies/mL) at week 24 was significantly lower compared to those with baseline HIV-1 RNA \u0026lt;100.000 copies/mL (80.4% vs. 93.8%, p\u0026lt;0.001). When using a threshold of \u0026lt;200 copies/mL, virological suppression rates at week 24 were 95% and 100%, respectively (p=0.028). No significant difference was observed in virological suppression rates at week 48 (98% vs. 100%, p=0.254).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAmong treatment-naive patients with baseline HIV-1 RNA \u0026gt;1.000.000 copies/mL, virological suppression rates (HIV-1 RNA \u0026lt;50 copies/mL) at weeks 24 and 48 were significantly lower compared to those with HIV-1 RNA \u0026lt;1.000.000 copies/mL (67.1% vs. 86.9%, p\u0026lt;0.001 and 88.4% vs. 94.5%, p=0.002, respectively). When using a threshold of HIV-1 RNA \u0026lt;200 copies/mL, the virological suppression rate at week 24 was 91.4% in patients with baseline HIV-1 RNA \u0026gt;1.000.000 copies/mL and 97% in those with \u0026lt;1.000.000 copies/mL\u0026nbsp;(p\u0026lt;0.001). At week 48, there was no significant difference in virological suppression rates between the two groups (98.4% vs. 98%, p=0.780).\u003c/p\u003e\n\u003cp\u003eAmong treatment-naive patients with baseline HIV-1 RNA \u0026gt;5.000.000 copies/mL, virological suppression rates at week 48 (HIV-1 RNA \u0026lt;50 copies/mL and \u0026lt;200 copies/mL) did not differ significantly from those with baseline HIV-1 RNA \u0026lt;5.000.000 copies/mL (85.3% vs. 93.3%, p=0.083 and 94.1% vs. 98.4%, p=0.114, respectively) (Table 3). \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 3. Virological suppression rates in treatment-naive patients before initiating BIC/FTC/TAF, and at weeks 24 and 48\u003c/strong\u003e\u003cstrong\u003e\u003cimg width=\"683\" height=\"367\" src=\"data:image/png;base64,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\" alt=\"A screenshot of a chart AI-generated content may be incorrect.\"\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAmong six treatment-na\u0026iuml;ve patients with baseline HIV-1 RNA \u0026gt;10.000.000 copies/mL; all five patients with available data at that time point achieved virological suppression (HIV-1 RNA \u0026lt;50 copies/mL) at week 48.\u003c/p\u003e\n\u003cp\u003eIn treatment‑experienced (switch) patients, week‑48 suppression was 92.2% (\u0026lt;50 copies/mL) and 96.5% (\u0026lt;200 copies/mL), compared to 85.6% and 92.5%, respectively, prior to switching.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAmong treatment-naive patients with a baseline CD4 count \u0026lt;350/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e, virological suppression rates (HIV-1 RNA \u0026lt;50 copies/mL) at weeks 24 and 48 were significantly lower compared to those with CD4 counts \u0026gt;350/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e (77.3% vs. 87.9%, p\u0026lt;0.001 and 90.8% vs. 95.7%, p=0.002, respectively).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAmong treatment-naive patients with a CD4 count \u0026lt;350/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e and baseline HIV-1 RNA \u0026gt;100.000 copies/mL, virological suppression rates at week 24 were 76.1% and 93.3% using thresholds of \u0026lt;50 copies/mL and \u0026lt;200 copies/mL, respectively. At week 48, the corresponding suppression rates were 90.8% and 97.6%. When compared to patients with baseline HIV-1 RNA \u0026lt;100.000 copies/mL, virological suppression rates at week 24 (using a threshold of \u0026lt;50 copies/mL) were significantly lower (76.1% vs. 92.5%, p=0.029).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAmong treatment-naive patients with a CD4 count \u0026lt;350 cells/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e and baseline HIV-1 RNA \u0026gt;1.000.000 copies/mL, virological suppression rates at week 24 were 65% and 89.6% using thresholds of \u0026lt;50 copies/mL and \u0026lt;200 copies/mL, respectively. At week 48, the corresponding suppression rates were 85.9% and 97.3%. Compared to patients with baseline HIV-1 RNA \u0026lt;1.000.000 copies/mL, virological suppression rates (threshold \u0026lt;50 copies/mL) at both week 24 and week 48 were significantly lower (65% vs. 83.5%, p\u0026lt;0.001; and 85.9% vs. 93.1%, p=0.008, respectively).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAmong patients with CD4 counts \u0026gt;350/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e, only those with baseline HIV-1 RNA \u0026gt;1.000.000 copies/mL had lower virological suppression rates (threshold \u0026lt;50 copies/mL) at week 24 compared to those with baseline HIV-1 RNA \u0026lt;1.000.000 copies/mL (73.3% vs. 90.3%, p\u0026lt;0.001).Among patients with CD4 counts \u0026lt;200/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e, the virological suppression rate (HIV-1 RNA \u0026lt;50 copies/mL) at week 48 was 91.6%. Among patients with CD4 counts \u0026lt;200/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e and HIV-1 RNA \u0026gt;1.000.000 copies/mL, the virological suppression rate (VL \u0026lt;50 copies/mL) at week 48 was 87.8%. In treatment‑na\u0026iuml;ve patients, the median CD4/CD8 ratio increased from 0.44 at baseline to 1.06 at week 48 (p\u0026lt;0.001) (Figure 4).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eChange in CD4 count\u003cu\u003e\u0026nbsp;\u003c/u\u003e(\u0026Delta;CD4 [cells/mm\u0026sup3;]) had median (25th\u0026ndash;75th) values of +139 (9.5\u0026ndash;263.1) at weeks 4\u0026ndash;8, +216 (85.75\u0026ndash;358) at week 24, and +263 (91\u0026ndash;416.5) at week 48; mean (\u0026plusmn;SD) changes were +136.3\u0026plusmn;211.7, +244.7\u0026plusmn;355.6, and +305.7\u0026plusmn;560.9, respectively.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIn treatment‑experienced patients, \u0026Delta;CD4 median values were \u0026minus;26.5 (\u0026minus;256.5 to 159.25) at weeks 4\u0026ndash;8, +86 (\u0026minus;100.0 to 257.0) at week 24, and +117.5 (\u0026minus;70.5 to 320.25) at week 48; mean changes were +67.6\u0026plusmn;376.1, +72.1\u0026plusmn;369.9, and +125.3\u0026plusmn;370.8, respectively.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eVirological and immunological outcomes in primary/early infection and older age\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAmong 215 treatment‑na\u0026iuml;ve patients with primary/early infection, median CD4 was 310 (169\u0026ndash;456) cells/mm\u0026sup3;; 57% had CD4 \u0026lt;350 and 31.2% \u0026lt;200 cells/mm\u0026sup3; at baseline. Baseline HIV‑1 RNA \u0026gt;100,000 and \u0026gt;1,000,000 copies/mL occurred in 93% and 28.4%, respectively. Virologic suppression at week 24 was 78.9% (\u0026lt;50 copies/mL) and 96.3% (\u0026lt;200 copies/mL); at week 48, corresponding suppression rates were 93.1% and 98.5%, respectively. Outcomes at week 48 were comparable to treatment‑na\u0026iuml;ve patients without primary/early infection.\u003c/p\u003e\n\u003cp\u003eAmong 68 treatment‑na\u0026iuml;ve patients aged \u0026ge;50 years, week‑48 virological suppression was 95% (\u0026lt;50 copies/mL) and 99% (\u0026lt;200 copies/mL).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSafety and tolerability\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eBaseline and week‑48 ALT, creatinine, and lipid parameters are summarized in Table 4. Non‑HDL cholesterol decreased significantly at week 48; total cholesterol/HDL ratios were comparable. Statin use during follow‑up was 8.5% (95/1122) among treatment‑na\u0026iuml;ve and 8.7% (99/1140) among treatment‑experienced patients.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 4. Biochemical Parameters Before BIC/FTC/TAF Initiation and at Week 48 of Treatment\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"567\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" rowspan=\"2\" style=\"width: 153px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eParameters\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 47px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eN\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 138px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eBefore B/F/TAF\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 156px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eweek 48\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 74px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep-value\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 138px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMedian (Q25-Q75)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 156px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMedian (Q25-Q75)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"4\" style=\"width: 40px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTreatment-Naive\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eALT\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 47px;\"\u003e\n \u003cp\u003e958\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 138px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e23 (18-29)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 156px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e21 (14-29.1)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 74px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCreatinine\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 47px;\"\u003e\n \u003cp\u003e987\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 138px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.83 (0.70-0.98)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 156px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.90 (0.78-1.00)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 74px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon-HDL Cholesterol\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 47px;\"\u003e\n \u003cp\u003e918\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 138px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e125 (97-157)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 156px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e120 (104-169)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 74px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTotal Cholesterol/HDL Ratio\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 47px;\"\u003e\n \u003cp\u003e918\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 138px;\"\u003e\n \u003cp\u003e4.08 (3.25-4.93)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 156px;\"\u003e\n \u003cp\u003e3.93 (3.23-4.93)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 74px;\"\u003e\n \u003cp\u003e0.998\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"4\" style=\"width: 40px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTreatment-Experienced\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eALT\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 47px;\"\u003e\n \u003cp\u003e1027\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 138px;\"\u003e\n \u003cp\u003e23 (18-28)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 156px;\"\u003e\n \u003cp\u003e22 (16-30.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 74px;\"\u003e\n \u003cp\u003e0.137\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCreatinine\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 47px;\"\u003e\n \u003cp\u003e1043\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 138px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.90 (0.75-1.05)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 156px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.90 (0.80-1.00)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 74px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon-HDL Cholesterol\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 47px;\"\u003e\n \u003cp\u003e943\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 138px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e140 (106-171)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 156px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e126 (104-176)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 74px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTotal Cholesterol/HDL Ratio\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 47px;\"\u003e\n \u003cp\u003e943\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 138px;\"\u003e\n \u003cp\u003e4.05 (3.17-4.93)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 156px;\"\u003e\n \u003cp\u003e3.93 (3.24-4.98)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 74px;\"\u003e\n \u003cp\u003e0.839\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eTreatment discontinuation\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNo serious adverse events leading to discontinuation were\u0026nbsp;recorded. BIC/FTC/TAF discontinuation occurred in 1.7% (na\u0026iuml;ve) and 2.6% (experienced) of patients (Table 5).\u003cu\u003e\u0026nbsp;\u003c/u\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 5. Reasons for BIC/FTC/TAF Discontinuation\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"463\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 392px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eReasons for B/F/TAF Discontinuation (Naive)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 71px;\"\u003e\n \u003cp\u003e\u003cstrong\u003en (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 392px;\"\u003e\n \u003cp\u003ePatient\u0026apos;s Decision\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 71px;\"\u003e\n \u003cp\u003e6 (31.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 392px;\"\u003e\n \u003cp\u003ePregnancy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 71px;\"\u003e\n \u003cp\u003e5 (26.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 392px;\"\u003e\n \u003cp\u003eOther\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 71px;\"\u003e\n \u003cp\u003e4 (21.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 392px;\"\u003e\n \u003cp\u003ePhysician\u0026apos;s Discretion\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 71px;\"\u003e\n \u003cp\u003e2 (10.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 392px;\"\u003e\n \u003cp\u003eUnknown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 71px;\"\u003e\n \u003cp\u003e2 (10.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 392px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eOverall\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 71px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e19 (100)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 392px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eReasons for B/F/TAF Discontinuation (Experienced)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 71px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 392px;\"\u003e\n \u003cp\u003eUnknown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 71px;\"\u003e\n \u003cp\u003e13 (43.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 392px;\"\u003e\n \u003cp\u003ePrevent potential future toxicities\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 71px;\"\u003e\n \u003cp\u003e5 (16.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 392px;\"\u003e\n \u003cp\u003eOther\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 71px;\"\u003e\n \u003cp\u003e5 (16.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 392px;\"\u003e\n \u003cp\u003ePhysician\u0026apos;s Discretion\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 71px;\"\u003e\n \u003cp\u003e3 (10)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 392px;\"\u003e\n \u003cp\u003ePatient\u0026apos;s Decision\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 71px;\"\u003e\n \u003cp\u003e2 (6.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 392px;\"\u003e\n \u003cp\u003ePregnancy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 71px;\"\u003e\n \u003cp\u003e2 (6.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 392px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eOverall\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 71px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e30 (100)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003ePrevious ART in Treatment-Experienced Patients\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAmong treatment-experienced patients, prior regimens before switching to BIC/FTC/TAF were as follows: EVG/COBI/FTC/TAF in 729 patients (64%), EVG/COBI/FTC/TDF in 114 patients (10%), DTG-based regimens in 193 patients (16.9%), raltegravir-based regimens in 26 patients (2.2%), protease inhibitor-based regimens in 57 patients (4.9%), and other regimens in 23 patients (2%). The median duration of previous ART use before switch was 48 months (IQR: 29\u0026ndash;72).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eReasons for Switching to BIC/FTC/TAF in Treatment-Experienced Patients\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn treatment‑experienced patients, the most common reasons for switching to BIC/FTC/TAF were physician discretion, prevention of potential future toxicities, and treatment simplification (Table 6).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 6. Reasons for Switching to BIC/FTC/TAF in Treatment-Experienced Patients\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"453\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eReasons for switching to BIC/FTC/TAF\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003en (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003ePhysician\u0026apos;s Discretion \u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e406 (35.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003ePrevent potential future toxicities\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e303 (26.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003eTreatment simplification\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e128 (11.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003eOther\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e91 (8)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003eUnknown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e70 (6.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003ePatient\u0026apos;s Decision\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e51 (4.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003eDrug-drug interactions\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e29 (2.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003eAdherence issues\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e19 (1.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003eIntolerance / toxicity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e16 (1.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003eVirological failure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e10 (0.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003ePlanned treatment interruption\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e5 (0.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003eNephrotoxicity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e4 (0.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003eEnhance the resistance barrier\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e4 (0.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003eImmunological failure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e4 (0.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 340px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eOverall\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 113px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e1140 (100)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e"},{"header":"DISCUSSION","content":"\u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003eVirological Suppression\u003c/h2\u003e \u003cp\u003eIn our study, which included a considerable proportion of treatment-naive PWH with high baseline viral loads, BIC/FTC/TAF demonstrated high rates of virological suppression at both week 24 and week 48. Virological suppression rates were 95.6% and 98.3%, respectively, when using a threshold of \u0026lt;\u0026thinsp;200 copies/mL, and 81.9% and 93% when using a threshold of \u0026lt;\u0026thinsp;50 copies/mL. Real-world studies of BIC/FTC/TAF have reported virological suppression rates at week 48 (threshold\u0026thinsp;\u0026lt;\u0026thinsp;50 copies/mL) ranging between 91.8% and 94% (\u003cspan additionalcitationids=\"CR14 CR15 CR16\" citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e). In a meta-analysis of real-world studies, the virological suppression rate at week 48 (threshold\u0026thinsp;\u0026lt;\u0026thinsp;50 copies/mL) was reported as 97% (\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e). In phase 3 studies of BIC/FTC/TAF, efficacy at week 48 in treatment-naive patients ranged from 89% to 92.4% (threshold\u0026thinsp;\u0026lt;\u0026thinsp;50 copies/mL) (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eTo date, both clinical trials and real-world studies have included a lower proportion of treatment-naive patients with high baseline viral loads compared to our study. An evaluation of the viral loads of patients included in the study indicates that baseline viral loads were higher compared to those reported in other studies (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan additionalcitationids=\"CR14 CR15\" citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e). In real-world studies, the proportion of treatment-naive patients with baseline HIV-1 RNA\u0026thinsp;\u0026gt;\u0026thinsp;100.000 c/mL ranges between 37.1% and 58.6%. (\u003cspan additionalcitationids=\"CR14 CR15\" citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e). In clinical trials, this proportion was reported at 17%, whereas in our study it was 88.5%(\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e). In real-world studies, the proportion of patients with HIV-1 RNA\u0026thinsp;\u0026gt;\u0026thinsp;500.000 c/mL was reported as 18.7% and 22% in two separate studies, while a phase 3 study reported 4% of patients with HIV-1 RNA\u0026thinsp;\u0026gt;\u0026thinsp;400.000 c/mL (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e). In our study, the proportion of patients with baseline HIV-1 RNA\u0026thinsp;\u0026gt;\u0026thinsp;500.000 c/mL was 46.4%, and 24.2% of patients had HIV-1 RNA\u0026thinsp;\u0026gt;\u0026thinsp;1.000.000 c/mL at baseline. We consider that the higher rates observed may be due to the high rate of late presentation in our cohort (with 51.5% of patients in the primary/early infection\u0026ndash;negative group having a CD4 count\u0026thinsp;\u0026lt;\u0026thinsp;350/mm\u0026sup3;) as well as the high proportion of primary/early infection cases.\u003c/p\u003e \u003cp\u003eIn our study, baseline HIV-1 RNA levels\u0026thinsp;\u0026gt;\u0026thinsp;100.000 c/mL and \u0026gt;\u0026thinsp;1.000.000 c/mL were found to significantly affect virological suppression rates at week 24. A similar pattern was observed in patients with higher baseline viral loads. Our findings support that in patients with high baseline viral loads, virological suppression may not be achieved by week 24, but may be achieved at substantially higher rates by week 48. Notably, despite the markedly higher proportion of treatment-naive patients with high baseline viral loads compared to other studies, the achievement of virological suppression rates comparable to those reported in the literature highlights the high efficacy of BIC/FTC/TAF. In patients with high baseline viral loads, lack of virological suppression at week 24 should not be a cause for concern; instead, the trajectory of viral load decline should be assessed, and follow-up should be conducted at appropriate intervals.\u003c/p\u003e \u003cp\u003eRegarding the potential impact of baseline CD4 counts on this outcome, the proportion of patients with baseline CD4\u0026thinsp;\u0026lt;\u0026thinsp;350/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e ranged from 33% to 35% in phase 3 studies and from 47.4% to 57% in real-world studies. The proportion of patients with CD4 counts\u0026thinsp;\u0026lt;\u0026thinsp;200/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e ranged from 11% to 14% in phase 3 studies and from 27.4% to 42% in real-world studies (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan additionalcitationids=\"CR14 CR15\" citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e). In our study, these proportions were 55.7% and 27.4%, respectively.\u003c/p\u003e \u003cp\u003eIn a subgroup analysis of two Phase 3 studies, Rampogal et al. reported a virological suppression rate (\u0026lt;\u0026thinsp;50 c/mL) of 99% at week 48 among 73 treatment-naive patients with baseline CD4 counts\u0026thinsp;\u0026lt;\u0026thinsp;200/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e. Among 39 patients with CD4 counts\u0026thinsp;\u0026lt;\u0026thinsp;200/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e and HIV-1 RNA\u0026thinsp;\u0026ge;\u0026thinsp;100.000 c/mL, the virological suppression rate was reported as 97% (\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e). Camacho et al. reported a virological suppression rate of 86.1% at week 48 in late presenters (\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e). The virological suppression rate at week 48 was 91.6% in treatment-naive patients with baseline CD4 counts\u0026thinsp;\u0026lt;\u0026thinsp;200/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e in our study.\u003c/p\u003e \u003cp\u003eIn our study, the association between a baseline CD4 count\u0026thinsp;\u0026lt;\u0026thinsp;350/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e and lower virological suppression rates at week 48\u0026mdash;compared to patients with CD4 counts\u0026thinsp;\u0026gt;\u0026thinsp;350/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e remained significant across all baseline viral load levels.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003eImmune Recovery\u003c/h2\u003e \u003cp\u003eIn our study, the median increase in CD4 count at week 48 in treatment-na\u0026iuml;ve patients was +\u0026thinsp;263 (IQR 91\u0026ndash;416.5). The mean increase was +\u0026thinsp;305.7\u0026thinsp;\u0026plusmn;\u0026thinsp;560.9. In phase 3 studies, this increase ranged from +\u0026thinsp;180 to +\u0026thinsp;233, while in the real-world BICSTaR study, the median increase was +\u0026thinsp;214 (IQR 120\u0026ndash;380). In the BICSTaR study, the proportion of patients with CD4\u0026thinsp;\u0026lt;\u0026thinsp;200/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e was 27.4%, and the proportion with CD4\u0026thinsp;\u0026lt;\u0026thinsp;350/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e was 47.4%. The proportion of patients with HIV-1 RNA\u0026thinsp;\u0026gt;\u0026thinsp;100.000 c/mL was reported as 37.1% (\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e). In Phase 3 studies, the proportion of patients with CD4 counts\u0026thinsp;\u0026lt;\u0026thinsp;200/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e ranged from 11% to 14%, and those with CD4 counts\u0026thinsp;\u0026lt;\u0026thinsp;350/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e ranged from 33% to 35%. The proportion of patients with HIV-1 RNA\u0026thinsp;\u0026gt;\u0026thinsp;100.000 c/mL was reported to range from 17% to 21% (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e). In our study, 55.7% of treatment-naive patients had CD4 counts\u0026thinsp;\u0026lt;\u0026thinsp;350/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e, 27.4% had CD4 counts\u0026thinsp;\u0026lt;\u0026thinsp;200/mm\u003csup\u003e\u0026sup3;\u003c/sup\u003e, and 88.5% had HIV-1 RNA levels\u0026thinsp;\u0026gt;\u0026thinsp;100.000 c/mL. We consider that the high proportion of patients with low CD4 counts and the high rate of primary/early infection in our study may explain the significant increases observed in CD4 counts.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003ePrimary / Early Infection\u003c/h2\u003e \u003cp\u003eIn a study by Ambrosioni et al., including 64 patients with primary/early infection the rate of virological supression was reported as 93% (\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e). In our study, including 215 individuals with primary/early infection, the virological suppression rate (\u0026lt;\u0026thinsp;50 c/mL) at week 48 was comparable at 93.1%.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003eTreatment-Experienced Patients\u003c/h2\u003e \u003cp\u003eIn treatment-experienced (switch) patients, the virological suppression rate at week 48 (\u0026lt;\u0026thinsp;50 c/mL) was 92.2%. In real-world studies, this rate is observed to range between 93.3% and 97% (\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e), while in phase 3 studies, it has been reported between 92% and 94% (\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eIn our study, the mean change in CD4 count at week 48 was +\u0026thinsp;125.3/mm\u0026sup3;. In previous studies, this change has been reported to range from a mean of \u0026minus;\u0026thinsp;31 to +\u0026thinsp;32 cells/mm\u0026sup3; (\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e). We consider that the duration of antiretroviral therapy prior to the switch may have contributed to these differences.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec21\" class=\"Section2\"\u003e \u003ch2\u003eTreatment Discontinuation and Safety\u003c/h2\u003e \u003cp\u003eIn our study, the overall treatment discontinuation rate was 1.7% in treatment-na\u0026iuml;ve patients and 2.6% in treatment-experienced patients. Esser et al. reported treatment discontinuation rates of 5% in treatment-na\u0026iuml;ve patients and 10% in treatment-experienced patients. Nasreddine et al. reported these rates as 8.3% and 6.1%, respectively (\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eIn our study, no treatment discontinuations due to drug-related adverse effects were observed. In phase studies, the discontinuation rate due to adverse effects in treatment-na\u0026iuml;ve patients ranged between 0% and 2%, while in real-world studies, it was reported as 3.7% (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e). In the switch studies, rates between 0% and 2% were reported (\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eWe were unable to perform pre-treatment antiretroviral resistance testing in our study. We believe this was due to the limited number of centers in our country that perform resistance testing and delays in obtaining test results. On the other hand, no resistance mutations associated with bictegravir have been demonstrated in studies. Sax et al. reported no treatment-emergent resistance during a 5-year follow-up period (\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e). Similarly, a very recent study conducted in our country found no resistance mutations associated with integrase inhibitors in treatment-na\u0026iuml;ve patients (\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eOur study has some limitations. These include its retrospective design, lack of monitoring for mild to moderate adverse events, absence of resistance data, unmonitored weight changes in patients, and a shorter follow-up period compared to the 240-week follow-up in studies 1489 and 1490. However, the strengths of our study are notable. First, it represents the largest multicenter real-world study conducted in T\u0026uuml;rkiye to date on BIC/FTC/TAF, actively involving 33 centers from various geographic regions. Secondly, it is the study that has included patients with the highest baseline viral loads among all studies conducted worldwide to date. Thirdly, it provides a detailed analysis of both virological and immunological responses in treatment-naive patients with low and high baseline viral loads.\u003c/p\u003e \u003c/div\u003e"},{"header":"CONCLUSIONS","content":"\u003cp\u003eBIC/FTC/TAF demonstrated both safety and efficacy in treatment-naive and treatment-experienced patients. Efficacy rates were particularly high in treatment-naive patients with high baseline viral loads, indicating that it can be used safely in this population.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eBIC/FTC/TAF: bictegravir/emtricitabine/tenofovir alafenamide\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePWH: people with HIV\u003c/p\u003e\n\u003cp\u003eKLİMİK: Turkish Society of Clinical Microbiology and Infectious Diseases\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eART: Antiretroviral Therapy\u003c/p\u003e\n\u003cp\u003eINSTI: Integrase Strand Transfer Inhibitors\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003eThis study was funded by Gilead Sciences.\u003c/p\u003e\n\u003cp\u003eThere is no conflict of interests.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eClinical trial number: not applicable.\u003c/p\u003e\n\u003cp\u003eHuman Ethics and Consent to Participate declarations: not applicable.\u003c/p\u003e\n\u003cp\u003eAvailability of data and materials: Corresponding author Halis Akalın [email protected]\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgments\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe would like to thank Dr. Guniz Kayahan and Dr. Ahmet Yilmaz from Gilead Sciences Türkiye for their support. We would like to thank Cem Şener from İNSİDANS for the biostatistical evaluation. AI was used for graphical abstract.\u003c/p\u003e\n\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eHA and VK proposed and developed research question. HA wrote the first draft of the manuscript. VK conducted the critical review. All authors contributed the study design, interpretation of data and the revision of the manuscript. All authors have seen and contributed to the final version of manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003ePeters E, Iwuji C. Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: a scoping review. Antivir Ther. 2023;:1\u0026ndash;15.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePanel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Updated Sep 25, 2025. Accessed Dec 15, 2025.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEuropean AIDS Clinical Society (EACS). Guidelines v13.0. Accessed Dec 15, 2025.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, et al. Bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir/abacavir/lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390:2063\u0026ndash;72.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWahl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir/abacavir/lamivudine for initial treatment of HIV-1: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6:e355\u0026ndash;63.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390:2073\u0026ndash;82.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOrkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, et al. Fixed-dose bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020;7:e389\u0026ndash;400.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E, et al. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. EClinicalMedicine. 2023;59:101991.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDaar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48-week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e347\u0026ndash;56.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMolina JM, Ward D, Brar I, Mills A, Stellbrink HJ, L\u0026oacute;pez-Cort\u0026eacute;s L, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir plus abacavir/lamivudine in virologically suppressed adults with HIV-1: 48-week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e357\u0026ndash;65.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGan L, Xie X, Fu Y, Yang X, Ma S, Kong L, et al. Bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir plus lamivudine for switch therapy in patients with HIV-1 infection: a real-world cohort study. Infect Dis Ther. 2023;12:2581\u0026ndash;93.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSax PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, Ward D, Trottier B, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults with HIV. Clin Infect Dis. 2021;73(2):e485\u0026ndash;93.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEsser S, Brunetta J, Inciarte A, Levy I, D\u0026rsquo;Arminio Monforte A, Lambert JS, et al. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: real-world insights from BICSTaR cohorts. HIV Med. 2024;25:440\u0026ndash;53.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eD\u0026rsquo;Arminio Monforte A, Tavelli A, Di Biaggio A, Sarmati L, Marchetti GC, Bai F, et al. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort. J Antimicrob Chemother. 2024;79:1279\u0026ndash;88.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTorralba M, Rodr\u0026iacute;guez G, Gasca FJG, Cuadra F, Barber\u0026aacute; J, Geijo P, et al. Bictegravir/emtricitabine/tenofovir alafenamide in a multicentre cohort: real-life experience from Spain. Ann Pharmacother. 2024;58(2):140\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAmbrosioni J, Lievano JR, Berrocal L, Inciarte A, de la Mora L, Gonz\u0026aacute;lez-Cord\u0026oacute;n A, et al. Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre. J Antimicrob Chemother. 2022;77:1133\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNasreddine R, Florence E, Yombi JC, Henrard S, Darcis G, Van Praet J, et al. Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium. HIV Med. 2023;24:914\u0026ndash;24.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChivite I, Berrocal L, de Lazzari E, Navadeh S, Lluis-Ganella C, Inciarte A, et al. Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV using real-world data: a systematic review and meta-analysis. J Antimicrob Chemother. 2024;79:1775\u0026ndash;83.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCrupi L, Parodi A, Cenderello G, Muccio M, Blanchi S, Randazzo N, et al. Impact of baseline plasma HIV-1 RNA and viral subtype on achievement of virological suppression in people with HIV treated with bictegravir/emtricitabine/tenofovir alafenamide in clinical practice. Sex Transm Infect. 2025;101(Suppl 1):A1\u0026ndash;207.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBegovac J, Lisicar I, Pintar VR, Zidovec-Lepej S, Planinic A, Zekan S. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide introduced at the first clinical visit: a real-life single-centre retrospective cohort study. Infect Dis Ther. 2025;14:867\u0026ndash;80.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRampogal M, Wurapa A, Baumgarten A, Berhe M, Pozniak A, Orkin C et al. Five-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two phase 3 randomized clinical trials. Presented at: IDWeek 2022; Oct 19\u0026ndash;23, 2022; Washington, DC, USA.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCorona D, P\u0026eacute;rez-Valero I, Camacho A, Liarte AG, Montero-Alonso M, Alem\u0026aacute;n MR, et al. Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters. Int J Antimicrob Agents. 2024;63:107016.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAmbrosioni J, de Lazzari E, Suanzes P, Busca C, Ruperta LR, Orviz E et al. Bictegravir/emtricitabine/tenofovir alafenamide for the treatment of primary HIV infection: the DIC-PHI clinical trial. Presented at: AIDS 2024; Jul 22\u0026ndash;26, 2024; Munich, Germany.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBlanco-Arevalo JL, Garc\u0026iacute;a-Deltoro M, Torralba M, V\u0026eacute;lez-D\u0026iacute;az-Pallares M, Castro A, Rubio-Rodr\u0026iacute;guez D, et al. HIV-1 resistance and virologic failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature review. AIDS Rev. 2024;26:67\u0026ndash;79.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e\u0026Ouml;zdemir A, Demir T, Polat C, Mertcan U, S\u0026ouml;nmezer M\u0026Ccedil;, Erg\u0026uuml;nay K, \u0026Uuml;nal S, İnkaya A\u0026Ccedil;, Pınar A. Molecular epidemiology and antiretroviral drug resistance profile, including capsid inhibitors, among treatment-na\u0026iuml;ve individuals with HIV-1 in T\u0026uuml;rkiye. HIV Med. 2025;:1\u0026ndash;9. Epub ahead of print.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"aids-research-and-therapy","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"arty","sideBox":"Learn more about [AIDS Research and Therapy](http://aidsrestherapy.biomedcentral.com/)","snPcode":"12981","submissionUrl":"https://submission.nature.com/new-submission/12981/3","title":"AIDS Research and Therapy","twitterHandle":"@BioMedCentral","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-8852078/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8852078/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePhase 3 trials have established the long‑term efficacy and safety of BIC/FTC/TAF for both treatment‑naïve and treatment‑experienced people with HIV (PWH). \u0026nbsp;Real‑world evidence in patients with very high baseline viral load remains limited.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis was a non‑interventional, observational, retrospective analysis across 33 tertiary centers participating in the KLIMIK HIV‑TR cohort. Adults (≥18 years) who initiated single‑tablet BIC/FTC/TAF on or before August 31, 2022 were included. The primary endpoint was virologic suppression at week‑48, defined as HIV‑1 RNA \u0026lt;200 copies/mL. Suppression was further stratified by baseline viral load (\u0026lt;100,000; \u0026gt;100,000; \u0026gt;1,000,000 copies/mL).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e2,262 patients were analyzed (1,122 treatment‑naïve [49.6%], 1,140 treatment‑experienced [50.4%]).\u003c/p\u003e\n\u003cp\u003eAmong treatment‑naïve patients, 88.5% had baseline HIV‑1 RNA \u0026gt;100,000 copies/mL and 24.2% \u0026gt;1,000,000 copies/mL; 55.7% had CD4 \u0026lt;350 cells/mm³. Virologic suppression (HIV-1 RNA \u0026lt;200 copies/mL) in treatment‑naïve patients was 95.6% and 98.3% at weeks 24 and 48 respectively. When a threshold of \u0026lt;50 copies/mL was used, virological suppression rates at weeks 24 and 48 were 81.9% and 93%, respectively. At week 24, virological suppression (HIV-1 RNA \u0026lt;50 copies/mL) was lower in those with baseline HIV‑1 RNA \u0026gt;100,000 versus \u0026lt;100,000 copies/mL (80.4% vs 93.8%; p\u0026lt;0.001), and lower in those with baseline HIV‑1 RNA \u0026gt;1,000,000 versus \u0026lt;1,000,000 copies/mL (67.1% vs 86.9%; p\u0026lt;0.001).\u003cu\u003e \u003c/u\u003eThe median CD4/CD8 ratio increased from 0.44 at baseline to 1.06 at week 48 (p\u0026lt;0.001).\u003c/p\u003e\n\u003cp\u003eNo serious adverse events leading to discontinuation were observed.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eHigh efficacy was observed even among treatment‑naïve patients with very high baseline viral loads, supporting its use in this population.\u003c/p\u003e","manuscriptTitle":"Effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV (PWH) in routine clinical practice in Türkiye: 12-month outcomes from the KLIMIK HIV- TR cohort","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-03-13 07:34:51","doi":"10.21203/rs.3.rs-8852078/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2026-04-10T16:34:52+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-04-06T01:33:32+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-04-04T16:10:43+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"274600871883581441485617764804231878746","date":"2026-03-31T02:33:12+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"194806250389370132325381278228118936804","date":"2026-03-25T13:30:34+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-03-10T00:58:58+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"109994089484620304758222248925800264871","date":"2026-03-09T09:51:14+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"126082143817218138931656423558087343689","date":"2026-03-06T20:53:43+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2026-03-06T15:38:54+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2026-02-14T05:10:50+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2026-02-13T07:31:54+00:00","index":"","fulltext":""},{"type":"submitted","content":"AIDS Research and Therapy","date":"2026-02-11T12:56:51+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"aids-research-and-therapy","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"arty","sideBox":"Learn more about [AIDS Research and Therapy](http://aidsrestherapy.biomedcentral.com/)","snPcode":"12981","submissionUrl":"https://submission.nature.com/new-submission/12981/3","title":"AIDS Research and Therapy","twitterHandle":"@BioMedCentral","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"4d0b2659-0337-4816-ae62-205f7cfd10d6","owner":[],"postedDate":"March 13th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2026-05-06T17:23:40+00:00","versionOfRecord":[],"versionCreatedAt":"2026-03-13 07:34:51","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8852078","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8852078","identity":"rs-8852078","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}